Study of Talabostat in Advanced Melanoma

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

The purpose of this study is to assess the antitumor activity and safety of talabostat in patients with metastatic melanoma.

Phase 2

Point Therapeutics